Physician profile
John D Stack
NPI 1629170592
$2,202.75
in general payments reported to CMS, 2019-2025
20 companies · $706 in 2025
The $706 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $169 · 2023: $341 · 2024: $862 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.41 | 2023-2025 | |
| Novo Nordisk INC | $182.87 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $168.05 | 2022-2025 | Jardiance, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $135.56 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $133.56 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.36 | 2022-2025 | Jardiance |
| Amgen INC. | $118.98 | 2024-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $85.63 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.54 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $56.67 | 2024-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $44.09 | 2021-2022 | |
| Mylan Specialty L.P. | $40.83 | 2022-2024 | Yupelri |
| Pfizer INC. | $38.26 | 2023-2024 | |
| Eisai INC. | $37.81 | 2021-2022 | |
| Astellas Pharma US INC | $32.66 | 2024 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $31.37 | 2023 | Opsumit, Uptravi |
| Dexcom, INC. | $18.97 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $18.87 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.